HE
Heilbron, E.
2 papers · 165 citations · 2025–2025
Publications
2
Citations
165
Years
1
Publications
| Title | Year | Type | Citations |
|---|---|---|---|
|
Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma
|
2025 | Meeting Abstract | 4 |
|
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer
|
2025 | Article | 161 |